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swimming in the same type of still waters (Lake Malawi 
for S. haematobium and Burkina Faso for S. mansoni). It 
must be kept in mind that location of the eggs in the 
spinal cord is due to aberrant migration, so it is rather 
surprising to note this rare phenomenon in our two 
patients. It has been previously reported that differences 
in schistosomiasis-associated morbidity may be ob- 
served between areas where prevalence and intensities 
of infection are comparable [lo]. The reasons for these 
differences are still not clear. 
The differences between patients depend on many 
factors, such as intensity and duration of infection, 
nutritional state, concomitant infections, differences in 
pathogenicity between local parasite strains, and host 
genetic differences [ l l ] .  Since the two patients were 
Caucasian, non-immune and in a normal nutritional 
state, and since they contracted schistosomiasis under 
similar conditions, it may be suggested that the spinal 
cord localization is either a random accident or due to 
a particular neurotropism of the strain. Intraspecific 
variation is widespread amongst Schistosoma spp. result- 
ing in differences in infection rate, egg distribution in 
tissues, maturation time, egg-laying capacity, patho- 
genicity, virulence, and susceptibility to drugs [12,13]. 
These differences may directly affect the epidemiology 
of schistosomiasis in various geographic areas. It would 
be of great interest to analyze the genomic patterns of 
strains isolated fkom areas where clinical manifestations 
are atypical. 
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Acrodermatitis chronica atrophicans and serologic 
confirmation of infection due to Borrelia afielii andlor 
Borrelia garinii by immunoblot 
Clin Microbiol Infect 1998; 4: 159-163 
Acrodermatitis chronica atrophicans (ACA) is a late 
chronic cutaneous manifestation of Lyme borreliosis 
[l], recognized almost exclusively in Europe [2]. Since 
1992, European isolates of Borrelia burgdorferi sensu lato, 
the agent causing Lyme disease have been subdivided 
into three major genospecies: B. burgdorferi sensu stricto. 
B. garinii and B. afielii [2,3]. Whereas B. burgdo~eri 
sensu stricto seems to be the major if not the only 
genospecies of clinical importance in North America, 
European isolates belong to three genospecies, mostly 
B. garinii or B. afielii [4]. Recent findings suggest that 
these three genospecies are associated with different late 
clinical manifestations, respectively to Lyme arthritis, 
neuroborreliosis and ACA [2,5-71. 
Because of its sometimes debilitating characteristics 
and its poor prognosis, ACA should be diagnosed and 
treated as soon as possible. Although B. burgdoferi sensu 
lato has been successfully cultured h-om various clinical 
lesions, culture remains a difficult procedure that is 
not practicable for routine diagnosis. Clinical diagnosis 
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is currently supported by measuring the antibody 
response to the spirochete: indirect immunofluo- 
rescence (IF) or enzyme-linked immunosorbent assays 
(ELISA) are routinely used. In these screening tests, 
whole cells or whole cell sonicated extract are used as 
antigens; this niay give rise to false-positive results 
due to cross-reaction with irrelevant antigens in the 
preparation. Apart from the problem of specificity, 
which can be partly resolved with ELISAs which 
use purified antigens such as the flagellum or the OspC 
or recombinant antigens such as p39 or an internal 
fragment of flagellin, these tests entail a loss of 
sensitivity in the specific antibody response to a single 
Borrelia species. 
The aim of the study was to develop a type-specific 
inimunoblot assay using whole cell lysates of each of 
the three genospecies to analyze the serologic response 
of patients with ACA. A total of 25 patients were 
retrospectively enrolled on the basis of dermatologic 
symptoms compatible with ACA and a positive 
screening test by ELISA (VIDAS Lyme IgG + IgM 
BioMkrieux, France). Results were confirmed by 
immunoblot using the detection of specific IgG to 
the three species of Borvelia. All 25 patient sera were 
screened for antibody to B. bitrgdorferi sensu lato using 
five other comniercial ELISA tests. 
The isolates used as antigens in the immunoblot 
assays were: VS 215 (B. hnydoferi  sensu stricto), VS 102 
(B .  garirzii), and VS 461 (B .  afrelii). Isolates used in this 
study were all low-passage strains (fewer than nine 
passages in BSK-I1 medium) isolated from Ixodes ricinus 
181. The three isolates were typed by phenotypic 
analysis [8] and genotypic analysis according to the 
method of Postic et a1 [9]. 
The SDS-PAGE and immunoblot assays were per- 
formed as previously described [8]. The criterion for a 
positive immunoblot with human serum was at least 
five bands including flagellin and two of the following 
specific bands: OspC, OspA, p39, 93 kDa (p100), as 
previously described 171. Immunoblots for the three 
species were performed with three strips, one for each 
species (VS 215, B. burgdoferi sensu stricto, VS 102, B. 
garinii, and VS 461, B. afielii).  They were prepared and 
incubated with serum from each patient and were 
processed through all stages in the same strip tray. 
For comparison between the three immunoblots, 
scores were allocated (0-3 points) according to the 
presence and intensity of the reaction to seven borrelia 
proteins, as shown in Figure l(a,b), 93 kDa (plOO), 
flagellin, p39, OspA, OspD, OspC and 18 kDa. This 
scoring system has been described and validated 
for neuroborreliosis [7].  A total score superior by 
two points for one individual species compared with 
the other species was defined as a specific reaction, 
based on a statistical analysis previously described 
[7] (for example, B 10, A 18, G 31 was typed as 
B. afzeliz]. This criterion was based on the significant 
differences observed in the statistical analysis of the 
mean scores. 
The sera of 23 patients with ACA were positive 
with six commercial ELISAs, while two sera were 
unreactive, each with one different ELISA, even though 
they were strongly reactive with the other five ELISAs 
(Table 1). 
The overall total scores established for the 25 
patients by immunoblot were as follows: 403 points for 
B. afielii,  319 points for B. gariiiii and 271 points for 
B. burgdorferi sensu stricto. Among the 25 patients 
reacting specifically with B. bn,:qdorfefevi sensu lato, 20, 
clearly demonstrated a stronger reaction to B. afiel i i  
(80%) (Figure la) ,  with a mean score of 4 above the 
other two species. Obvious specific reactions to B. 
garinii were observed in two patients (8%) (Table 1, nos. 
4 and 9; Figure lb) and reactions to both B. afielii and 
B. garinii were found in three patients (12%) (Table 1,  
nos. 3,  11 and 16). No preferential reactivity to B. 
hurgdorferi sensu stricto was observed. 
This study clearly demonstrated the association 
between B. afzelii and ACA. Pifferentiation of the 
specific reactivity was quite obvious in the immuno- 
blots, as observed by Assous et a1 [6]. The numerical 
scores allowed us to define the specific reactivities on a 
semiquantitative basis. In 20 of 25 patients (80%) the 
score was definitely higher for B. qfrelii. In three 
additional patients we niay suspect on the basis of the 
serologic reactions a dual infection by B. ufzelii and B. 
xarinii, as previously described by Demaerschalk et a1 
[lo] in patients with neuroborreliosis. Two of the 25 
cases (8%) showed an  unequivocally stronger reaction 
to B. gaviizii. Recently, Rijpkenia et a1 [I 11 amplified by 
polymerase chain reaction (PCR) B. garinii genonlic 
material from the skin of patients with ACA and also 
detected mixed infection by B. afielii and B. gaririii. 
These results seem to indicate that the association 
between particular Borrelia genospecies and clinical 
manifestations is real but not absolute. Unfortunately, 
no skin biopsy was available for P C R  confirmation in 
the two above mentioned cases. 
A similar association between B. garinii and neuro- 
borreliosis was observed among a group of 28 patients 
with neuroborreliosis. In this study [7], we used the 
same immunoblots, and we showed that scores were 
higher for B. garinii (353 points) than for B. afielii (29 1 
points) and for B. burgdoferi sensu stricto (283 points). 
Overall, 64% (18/28) of these patients with neuro- 
borreliosis showed a stronger antibody reaction to 
B. garinii, 11% (3/28) to B. btrrgdorferi sensu stricto and 
7% (2128) to B. afzelii. These results were significantly 
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Figure la) Example of predominant score to Borrelia afrelii (A). Figure lb) Example of predominant score to Borrelia 
garinii (G). Immunoblots (IgG) with the serum of patients with ACA and three strips: B: VS 215, B. burgdoferi sensu stricto; 
A: VS 461, B. afielii, G: VS 102, B. garinii. Score points are allocated to 93-kDa protein, flagellin, p39, C)spA, OspD, OspC 
and 18-kDA protein. 
different (p<0.02) from those of a control group of 20 
patients with erythema migrans. 
Although the diagnosis of Lyme disease is primarily 
based on clinical manifestations, laboratory data are 
frequently necessary to elucidate borderline clinical 
presentations. The direct detection of the causative 
agent is impaired by the low number of borreliae 
present in tissue and especially in body fluids. Even the 
highly sensitive P C R  seems not to be superior to the 
conventional culture isolation methods [12], except for 
synovial fluid, from which borreliae have rarely been 
isolated but have been demonstrated by P C R  in up to 
96% of untreated Lyme arthritis cases 1131. Serologic 
techniques are, therefore, the most widely used methods 
to establish the diagnosis of Lyme borreliosis. Several 
attempts to increase the sensitivity and specificity of 
serologic tests have included absorption procedures 
with Eeponema phagedenis, use of purified antigens or 
recombinant antigens and the association of different 
recombinant antigens selected from different strains in 
the same immunoblot [14]. The four antigens studied 
by Wilske et a1 were flagellin, an internal flagellin 
fragment, the 93-kDa protein called p100, the plasmid- 
encoded outer-surface proteins OspA and OspC. The 
authors concluded that recombinant antigens from 
different genospecies of B. burgdoferi sensu lato are 
serologically different, and that specific clinical mani- 
festations are correlated with each of the three 
genospecies. Therefore, genospecific tests for each 
clinical indication could provide more sensitivity and 
specificity than a single common test. 
The type-specific assay described here is based 
on seven antigens-93 kDa or p100, flagellin, p39, 
OspA, OspD, OspC and 18-kDa proteins specifically 
recognized in each of the three genospecies. In this 
study, each serum was tested for the presence of specific 
IgG against all these antigenic proteins of each of the 
three genospecies. The serologic data in the present 
study show a clear association of B. ufzelii with ACA 
and confirm the results of isolations typed as B. ufielii 
from the skin of patients with ACA [2,15]. Further- 
more, our data strongly suggest that B. garinii is also 
able to produce chronic dermatologic disorders such 
as ACA, though at a much lower frequency than B. 
afielii.  This is, to the best of our knowledge, the first 
report of serologic determination of B. garinii as the 
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Table 1 Serologic results of 25 patients with acrodermatitis 
c h ro n i ca atroD hicans 
Immunoblot scores Patirnt 
no. ELlSA B A G Interpretation 
1 +++ 
2 +++ 
3 +++ 
3 ti+ 
3 +++ 
6 ++ 
7 +++ 
8 ++ 
9 -/+++ 
I 0  +++ 
I t  +++ 
12 +++ 
13 +++ 
14 ++f 
15 +++ 
16 +++ 
17 +++ 
18 ++ 
19 +++ 
2( 1 +++ 
21 +++ 
22 +++ 
23 -/+++ 
23 +++ 
25 +++ 
Total 
12 
13 
6 
13 
12 
12 
x 
9 
9 
10 
8 
11 
13 
7 
8 
11 
14 
11 
14 
9 
13 
1 0 
13 
10 
27 1 
15 
14 I 1  
18 12 
15 14 
14 18 
18 14 
19 12 
13 10 
21 11 
10 17 
I Y  12 
14 14 
16 13 
16 11 
17 14 
18 10 
13 13 
18 14 
20 14 
15 12 
17 15 
15 10 
15 11 
15 12 
18 13 
14 12 
403 319 
8. aJzelii 
B.  aJzelii 
8. aJzelii-B. garinii 
8. garinii 
B. aJrelii 
B. aJzelii 
B. aJrelii 
B. aJzelii 
B. garinii 
B. aJzelii 
B. afielii-B. garinii 
B. aJzelii 
B. aJzelii 
8. aJzelii 
B. afielii 
B. afielii-B. xarinii 
B. afzelii 
B. afiplii 
B. afzelii 
B. afrelii 
B. ayzelii 
B. afrelii 
B. qfzelii 
B. afie/ii 
B. ajzelii 
lmtnunoblot: B, B. brr@or$!ri sensu stricto; A, €3. afielii; G, B. garinii. 
causative agent of ACA. Dual infection with B. ufielii 
and B. garinii or reinfection with one or the other 
genospecies may be suspected in patients reacting 
with both B. afielii and B. garinii. The immunoblot 
described here also allows the discrimination of false- 
positive reactions in screening tests and occasionally 
the confirmation of a chronic Lyme borreliosis in 
spite of a negative ELISA. It therefore seems to be a 
sensitive and specific confirmatory test in the labora- 
tory diagnosis of chronic Lyme borreliosis. 
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High intraplatelet cGMP levels in human sepsis 
Clin Microbiol Infect 1998; 4: 163-165 
Nitric oxide (NO) is synthesized from L-arginine by 
a group of enzymes, the nitric oxide synthases (NOS). 
Under normal circumstances the endothelial constitutive 
isoform releases small quantities of NO, which acts 
as an endogenous vasodilator and inhibits platelet 
adhesion and aggregation [l]. These actions are 
mediated by the activation of soluble guanylate cyclase 
which increases the concentration of cyclic guanosine 
monophosphate (cGMP) in target cells. Expression of 
the inducible NOS isoform is activated in various cells 
(endothelium, smooth muscle, macrophages, etc.) 
in response to inflammatory cytokines and bacterial 
lipopolysaccharide (LPS). This enzyme synthesizes 
large quantities of N O  which play a significant role 
in the characteristic hemodynamic changes of septic 
shock 111. There are indirect data supporting the idea 
of increased production of N O  during sepsis. High 
plasma and urine levels of NOz/NO3 (inactive meta- 
bolic end products of NO) have been demonstrated in 
sepsis in both animals [2] and humans [3]. Both in 
endotoxin treated rats [4] and in human septic shock 
[5], an increase in plasma cGMP levels has been 
observed. 
Keaney et al [6] have recently reported that LPS- 
induced shock in rabbits increases intraplatelet cGMP 
levels, reflecting the effect of high amounts of NO on 
these cells. Intraplatelet cGMP levels are considered to 
be a good index of the global NO pathway activity 
[1,7,8]. We hypothesized that the high production of 
NO in human sepsis should produce an increase in 
intraplatelet cGMP. We therefore measured intra- 
platelet cGMP levels in a group of septic patients and 
correlated these with other clinical and biochemical 
parameters. 
Twelve patients with sepsis (five men and seven 
women), aged 61 k 20 years (mean k standard deviation), 
were studied. Patients were eligible for study if they 
fulfilled the sepsis criteria of the American College of 
Chest Physician Society and Critical Care Medicine 
Association [9]. Table 1 shows clinical and biochemical 
parameters. Patients with acquired immunodeficiency 
syndrome, active tuberculosis, neoplasia, autoimmune 
and hematologic diseases, and patients who had 
received antiplatelet drugs, glucocorticoids, immuno- 
suppressants or antibiotics before the diagnosis, were 
excluded. The control group comprised 12 age- and 
sex-matched healthy volunteers (four men and eight 
women) aged 52 k 11 years. Informed consent was 
obtained &om all patients and volunteers and the research 
was approved by a local human investigations com- 
mittee in accordance with the Helsinki Declaration. 
Blood samples for cGMP determinations were 
collected into 0.105 M sodium citrate from the cubital 
vein, at diagnosis before starting antibiotic treatment 
(day 0), and 1 (day 1) and 7 days later (day 7). Plasma 
and intraplatelet cGMP was measured as described 
previously [7]. Serum creatinine levels were deter- 
nlined by the Jaffi- kinetic method in Autoanalyzer 
Hitachi 737 (Boehringer Mannheim, Mannheim, 
Germany). 
All data were analyzed using Statistical Package for 
Social Sciences software. Since the data distribution was 
non parametric, results are expressed as median and 
range. The Mann-Whitney rank-sum test was used 
for the comparisons between groups. Correlations 
were done with the Spearman test. Differences were 
considered significant if p < 0.05. 
As shown in Figure 1, day 0 intraplatelet cGMP 
levels were higher in the septic patients (0.87 
(0.35-5.06) pmol/109 platelets (median and range)), 
than in the control group, 0.23 (0.1-0.4) pmol/109 
platelets; p = 0.0001). Plasma cGMF’ levels were also 
significantly increased in the septic patients (4.39 
(1.59-13.78) nmol/L), when compared with the 
control group (1.87 (1.09-4.06) nmol/L, p=0.02). 
We did not find significant correlations between plasma 
or intraplatelet cGMP levels and number of platelets, 
diastolic blood pressure (DBP), systolic blood pressure 
(SBP), APACHE I1 score or serum creatinine levels at 
day 0. 
In septic patients intraplatelet cGMP levels were 
1.06 (0.19-4.80) pmol/109 platelets at day 1> and 0.58 
(0.32-2.60) pmol/109 platelets at day 7; plasma cGMP 
levels were 4.94 (2.21-1 1.96) nmol/L at day 1 and 2.82 
(2.39-6.06) nmoI/L at day 7. Intraplatelet cGMP levels 
did not change significantly after antibiotic treatment 
within the period of time studied. On the contrary, 
plasma cGMP levels of septic patients at day 7 had 
reached normal levels. 
Our study demonstrates for the first time that 
intraplatelet cGMP levels are increased in septic 
